LONDON (Reuters) - GlaxoSmithKline is betting on a new vaccine technology based on chimpanzee viruses by acquiring Swiss-based Okairos for 250 million euros (321 million U.S. dollars) - the latest bolt-on biotech buy by a big drugmaker.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment